v3.26.1
Strategic Collaboration, Supply and Securities Purchase Agreements with Tolmar (Details) - USD ($)
$ in Thousands
1 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2026
Jun. 30, 2026
Dec. 31, 2025
Strategic Collaboration, Supply and Securities Purchase Agreements with Tolmar [Line Items]        
Trading day volume weighted average price     30 days  
Milestone payment     $ 65,000  
Customer non-refund payments $ 15,000      
Excess over fair value paid 3,878      
Percentage of ordinary share premium     25.00%  
Revenue recognized      
Estimated the transaction price 38,878 $ 38,878 38,878  
Unconstrained milestone payment 20,000      
Deferred revenue 18,878 $ 18,878 18,878
One Clinical [Member]        
Strategic Collaboration, Supply and Securities Purchase Agreements with Tolmar [Line Items]        
Milestone payment     $ 20,000  
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Tolmar [Member]        
Strategic Collaboration, Supply and Securities Purchase Agreements with Tolmar [Line Items]        
Percentage of net sales of the product adjustments   60.00%    
Tolmar Agreements [Member]        
Strategic Collaboration, Supply and Securities Purchase Agreements with Tolmar [Line Items]        
Trading day volume weighted average price     30 days  
Milestone payment     $ 96,500  
Payment for manufacturing     5,000  
Customer non-refund payments     15,000  
Contract liability 3,878 $ 3,878 $ 3,878  
Percentage of ordinary share premium     25.00%  
Term of commercial sale of the product agreement   20 years    
Deferred revenue $ 18,878 $ 18,878 $ 18,878  
Payment for issuance of equity securities     $ 20,000